UBS Maintains Buy on Guardant Health, Raises Price Target to $225
Benzinga Newsdesk 1 month ago
NewsPrice TargetAnalyst Ratings
UBS analyst Dan Leonard maintains Guardant Health (NASDAQ:GH) with a Buy and raises the price target from $175 to $225.
UBS analyst Dan Leonard maintains Guardant Health (NASDAQ:GH) with a Buy and raises the price target from $175 to $225.